monoclonal antibodies

September 13, 2023

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

By Bill Snyder
James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)
August 4, 2023

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

By Anthony Czelusniak
Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.
June 22, 2023

VUMC, Oxford team develops ‘blueprint’ to block lethal virus

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.

By Bill Snyder
March 23, 2023

Crowe’s research honored

Vanderbilt’s James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization’s annual awards program in Washington, D.C.

By VUMC News and Communications
March 16, 2023

Scientists resurrect a ‘dead’ antibody to study protein

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.

By Bill Snyder
array of test tubes with pipette dropping fluid into one
February 2, 2023

VU, VUMC rise in National Science Foundation survey

Vanderbilt University and Vanderbilt University Medical Center climbed seven spots in a survey by the National Science Foundation that measures annual research and development expenditures.

By VUMC News and Communications
January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.
By Bill Snyder
November 10, 2022

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.
By Bill Snyder
November 3, 2022

Event to spotlight VUMC’s COVID-19 research efforts

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
By Bill Snyder
October 6, 2022

Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.
By Bill Snyder
October 3, 2022

Minority patients less likely to have amyloid plaques necessary for Alzheimer’s treatments

Fewer Black, Hispanic and Asian patients meet biomarker qualifications for landmark treatments that may slow the progression of Alzheimer’s disease by targeting amyloid plaques, according to new findings published in JAMA Neurology.
By Holly Fletcher
September 29, 2022

VUMC lands grant to build top-line biosafety facility

Vanderbilt University Medical Center is set to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms.
By Bill Snyder
August 24, 2022

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
By Bill Snyder
1 2 3 4 … 9